Pentetic Acid

Summary

Pentetic Acid (CHEMBL780) is an approved small-molecule copper chelator; indicated across 2 conditions including lymphoma and brain neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 11
• Chemistry: 393.35 Da · C14H23N3O10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL780
Name	Pentetic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3053
ChEBI	CHEBI:35739
Molecular formula	C14H23N3O10
Molecular weight	393.35
InChIKey	QPCDCPDFJACHGM-UHFFFAOYSA-N

SMILES: C(CN(CC(=O)O)CC(=O)O)N(CCN(CC(=O)O)CC(=O)O)CC(=O)O

IUPAC name: 2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid

Pharmacological roles (ChEBI): copper chelator.

Also known as: Acide pentetique, Acido pentetico, DTP-A, DTPA, Nanodtpa, NSC-7340, Pentetic acid, Diethylenetriaminepentaacetic acid, SID11111089, SID11111090, SID26753562, SID50106210

Parent form; salt/anhydrous children: CHEMBL1200424, CHEMBL1200945

Patent coverage: 24,935 distinct patent families (71,355 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, Prelamin-A/C, RecQ-like DNA helicase BLM, Endonuclease 4, Peripheral myelin protein 22, Alpha-2A adrenergic receptor, Thyrotropin receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, D(3) dopamine receptor, Sodium-dependent dopamine transporter, Histamine H3 receptor, Polyunsaturated fatty acid lipoxygenase ALOX15, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 21 potent at pChembl ≥ 5 of 30 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	8.6	Potency	2.5	nM	CHEMBL_ACT_4014261
CYP2C19	8.6	AC50	2.51	nM	CHEMBL_ACT_6004214
SLC6A4	7.37	AC50	42.9	nM	CHEMBL_ACT_25151125
LMNA	6.9	Potency	125.9	nM	CHEMBL_ACT_3663352
TDP1	6.7	Potency	199.5	nM	CHEMBL_ACT_3932929
TDP1	6.65	Potency	223.9	nM	CHEMBL_ACT_3937724
BLM	6.35	Potency	446.7	nM	CHEMBL_ACT_4750007
BLM	6.35	Potency	446.7	nM	CHEMBL_ACT_4937916
P0A6C1	6.15	Potency	707.9	nM	CHEMBL_ACT_4069585
ALOX15	6.1	Potency	794.3	nM	CHEMBL_ACT_4454723
ADRA1A	5.89	AC50	1282	nM	CHEMBL_ACT_25218680
ADRA2A	5.88	AC50	1319	nM	CHEMBL_ACT_25156227
DRD3	5.64	AC50	2265	nM	CHEMBL_ACT_25194325
TDP1	5.5	Potency	3162	nM	CHEMBL_ACT_3935817
CHRM2	5.41	AC50	3914	nM	CHEMBL_ACT_25195534
A8B2U2	5.4	Potency	3972	nM	CHEMBL_ACT_4586268
KDM4E	5.2	Potency	6310	nM	CHEMBL_ACT_3740956
ALOX15	5.2	Potency	6310	nM	CHEMBL_ACT_4463601
SLC6A3	5.19	AC50	6511	nM	CHEMBL_ACT_25124757
A8B2U2	5.1	Potency	7924	nM	CHEMBL_ACT_4609814
DRD1	5.06	AC50	8707	nM	CHEMBL_ACT_25115008

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
lymphoma	1	MONDO:0005062	EFO:0000574
brain neoplasm	1	MONDO:0021211	EFO:0003833

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	5
PHASE1/PHASE2	2
PHASE2	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07596173	PHASE3	NOT_YET_RECRUITING	A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years
NCT07596199	PHASE3	NOT_YET_RECRUITING	A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women
NCT00290342	PHASE3	COMPLETED	Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants
NCT01027845	PHASE3	COMPLETED	Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children
NCT05169905	PHASE3	COMPLETED	A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
NCT00019227	PHASE1/PHASE2	COMPLETED	Monoclonal Antibody Therapy in Treating Patients With Leukemia
NCT00126984	PHASE2	COMPLETED	Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine
NCT02946190	PHASE2	COMPLETED	The PertADO Geneva Trial
NCT02947022	PHASE1/PHASE2	TERMINATED	Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease
NCT01034514	EARLY_PHASE1	TERMINATED	4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
NCT02278510	EARLY_PHASE1	COMPLETED	Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).